Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Recommendation of "Moderate Buy" from Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $211.91.

Several equities analysts have recently commented on the company. Morgan Stanley lowered their price objective on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. KeyCorp lowered their price target on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Robert W. Baird upped their price target on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada lowered their target price on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a report on Tuesday, April 15th.

Inspire Medical Systems Trading Down 1.4%

NYSE INSP traded down $1.75 on Friday, reaching $126.86. 983,733 shares of the stock were exchanged, compared to its average volume of 565,307. Inspire Medical Systems has a one year low of $123.00 and a one year high of $225.00. The firm has a market capitalization of $3.74 billion, a PE ratio of 73.33, a PEG ratio of 2.86 and a beta of 1.28. The company's 50-day simple moving average is $147.79 and its two-hundred day simple moving average is $170.29.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The firm had revenue of $201.32 million for the quarter, compared to the consensus estimate of $194.89 million. During the same period last year, the firm earned ($0.34) EPS. The company's revenue was up 22.7% on a year-over-year basis. Sell-side analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Shawn Mccormick sold 360 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the sale, the director now directly owns 24,046 shares in the company, valued at $3,847,360. The trade was a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dragoneer Investment Group LLC purchased a new stake in Inspire Medical Systems during the fourth quarter valued at approximately $161,486,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Inspire Medical Systems by 214.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company's stock valued at $177,267,000 after purchasing an additional 759,090 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in Inspire Medical Systems during the 4th quarter valued at $80,419,000. Congress Asset Management Co. raised its holdings in Inspire Medical Systems by 3,943.6% during the 1st quarter. Congress Asset Management Co. now owns 307,555 shares of the company's stock valued at $48,987,000 after buying an additional 299,949 shares during the period. Finally, Marshall Wace LLP lifted its position in Inspire Medical Systems by 1,775.3% in the fourth quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock worth $51,375,000 after buying an additional 262,353 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.